Journal article
Survival by colon cancer stage and screening interval in Lynch syndrome: A prospective Lynch syndrome database report
M Dominguez-Valentin, TT Seppälä, JR Sampson, F MacRae, I Winship, DG Evans, RJ Scott, J Burn, G Möslein, I Bernstein, K Pylvänäinen, L Renkonen-Sinisalo, A Lepistö, A Lindblom, JP Plazzer, D Tjandra, H Thomas, K Green, F Lalloo, EJ Crosbie Show all
Hereditary Cancer in Clinical Practice | BMC | Published : 2019
Open access
Abstract
Background: We previously reported that in pathogenic mismatch repair (path-MMR) variant carriers, the incidence of colorectal cancer (CRC) was not reduced when colonoscopy was undertaken more frequently than once every 3 years, and that CRC stage and interval since last colonoscopy were not correlated. Methods: The Prospective Lynch Syndrome Database (PLSD) that records outcomes of surveillance was examined to determine survival after colon cancer in relation to the time since previous colonoscopy and pathological stage. Only path-MMR variants scored by the InSiGHT variant database as class 4 or 5 (clinically actionable) were included in the analysis. Results: Ninety-nine path-MMR carriers ..
View full abstractGrants
Awarded by Wilhelm Sander-Stiftung
Funding Acknowledgements
[ "TTS and J-PM are supported by the Emil Aaltonen Foundation, the Finnish Medical Foundation, the Instrumentarium Science Foundation, Sigrid Juselius Foundation, The Finnish Cancer Foundation, Jane and Aatos Erkko foundation and State Research Funding.", "DGE and EJC are both supported through the National Institute for Health Research Manchester Biomedical Research Centre (IS-BRC-1215-20007).", "The Spanish contribution: GC and MP were funded by the Spanish Ministry of Economy and Competitiveness and cofunded by FEDER funds - a way to build Europe-(grant SAF2015-68016-R) and the CIBERONC, the Carlos III Health Institute, the Scientific Foundation Asociacion Espanola Contra el Cancer and the Government of Catalonia.", "The Welsh Contribution: Wales Gene Park.", "The Norwegian contribution: Norwegian Cancer Society, contract 194751-2017 for funding.", "Work relevant for the German contribution was funded in part by Wilhelm Sander Foundation (2016.056.1) and German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; KFO227, KL2354)." ]